These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 26339722)

  • 1. A canine biorelevant dissolution method for predicting in vivo performance of orally administered sustained release matrix tablets.
    Walsh PL; Bothe JR; Bhardwaj S; Hu M; Nofsinger R; Xia B; Persak S; Pennington J; Bak A
    Drug Dev Ind Pharm; 2016; 42(5):836-44. PubMed ID: 26339722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
    Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
    Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel in vivo predictive dissolution testing coupled with a modeling and simulation for hydrogel matrix monolithic extended release oral dosage forms.
    Kambayashi A; Dressman JB
    Eur J Pharm Sci; 2019 Oct; 138():105044. PubMed ID: 31421255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A physiologically-based drug absorption modeling for orally disintegrating tablets.
    Kambayashi A; Kiyota T
    Eur J Pharm Biopharm; 2020 Jul; 152():1-9. PubMed ID: 32371153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations.
    Tajiri S; Kanamaru T; Kamada M; Konno T; Nakagami H
    Int J Pharm; 2010 Jan; 383(1-2):99-105. PubMed ID: 19747964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state.
    Arndt M; Chokshi H; Tang K; Parrott NJ; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2013 Aug; 84(3):633-41. PubMed ID: 23434923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
    Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QbD-Oriented Development and Characterization of Effervescent Floating-Bioadhesive Tablets of Cefuroxime Axetil.
    Bansal S; Beg S; Garg B; Asthana A; Asthana GS; Singh B
    AAPS PharmSciTech; 2016 Oct; 17(5):1086-99. PubMed ID: 26527606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scintigraphic evaluation of the in vivo performance of dry-coated delayed-release tablets in humans.
    Kambayashi A; Sako K; Kondo H
    Eur J Pharm Biopharm; 2020 Jul; 152():116-122. PubMed ID: 32380166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution testing of oral modified-release dosage forms.
    Garbacz G; Klein S
    J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrated system for dissolution studies and magnetic resonance imaging of controlled release, polymer-based dosage forms-a tool for quantitative assessment of hydrogel formation processes.
    Kulinowski P; Dorozyński P; Jachowicz R; Weglarz WP
    J Pharm Biomed Anal; 2008 Nov; 48(3):685-93. PubMed ID: 18715732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
    Kambayashi A; Blume H; Dressman JB
    Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulating Different Dosing Scenarios for a Child-Appropriate Valproate ER Formulation in a New Pediatric Two-Stage Dissolution Model.
    Karkossa F; Krueger A; Urbaniak J; Klein S
    AAPS PharmSciTech; 2017 Feb; 18(2):309-316. PubMed ID: 27909943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the Dissolution Profile of Gliclazide Modified-Release Tablets Using Different Apparatuses and Dissolution Conditions.
    Skripnik KKS; Riekes MK; Pezzini BR; Cardoso SG; Stulzer HK
    AAPS PharmSciTech; 2017 Jul; 18(5):1785-1794. PubMed ID: 27800567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico and in vitro methods to optimize the performance of experimental gastroretentive floating mini-tablets.
    Eberle VA; Häring A; Schoelkopf J; Gane PA; Huwyler J; Puchkov M
    Drug Dev Ind Pharm; 2016; 42(5):808-17. PubMed ID: 26307090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biorelevant in vitro performance testing of orally administered dosage forms-workshop report.
    Reppas C; Friedel HD; Barker AR; Buhse LF; Cecil TL; Keitel S; Kraemer J; Morris JM; Shah VP; Stickelmeyer MP; Yomota C; Brown CK
    Pharm Res; 2014 Jul; 31(7):1867-76. PubMed ID: 24643933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.